dr. HM (Hedwig) Blommestein

Erasmus School of Health Policy & Management

Associate professor | Health Technology Assessment (HTA)

Email: blommestein@eshpm.eur.nl

Pure profile

Work

M. R. Seefat, C. A.M. Stege, B. I. Lissenberg-Witte, M. D. Levin, G. J. Timmers, M. Hoogendoorn, P. F. Ypma, S. K. Klein, G. A. Velders, M. Westerman, L. Strobbe, N. Durdu-Rayman, M. A. Davidis-van Schoonhoven, R. J.W. van Kampen, A. C. Dijk, A. Koster, M. H. Silbermann, E. van der Spek, A. Beeker, Z. Erjavec, N. C.H.P. de Graauw, M. B.L. Leys, P. Sonneveld, N. W.C.J. van de Donk, K. Nasserinejad, H. M. Blommestein, D. G.J. Cucchi & S. Zweegman (2024) - Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial - European Journal of Cancer, 207 - doi: 10.1016/j.ejca.2024.114153 - [link]
Christine Bennink, Mirian Brink, Saskia F.A. Duijts, Hans Scheurer, Pieter Sonneveld & Hedwig M. Blommestein (2024) - Changes in income and employment after diagnosis among patients with multiple myeloma in The Netherlands - Clinical Lymphoma, Myeloma and Leukemia, 24 (9), 604-610 - doi: 10.1016/j.clml.2024.04.004 - [link]
M. R. Seefat, D. G.J. Cucchi, K. Groen, M. L. Donker, K. G. van der Hem, M. Westerman, A. M. Gerrits, A. Beeker, N. W.C.J. van de Donk, H. M. Blommestein & S. Zweegman (2024) - Treatment sequences and drug costs from diagnosis to death in multiple myeloma - European Journal of Haematology, 112 (3), 360-366 - doi: 10.1111/ejh.14119 - [link]
Marianne Luyendijk, Agnes Jager, Sanne M. Buijs, Sabine Siesling, Carin A.Uyl de Groot & Hedwig M. Blommestein (2023) - Cost-Effectiveness Analysis of MammaPrint<sup>®</sup> to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer - PharmacoEconomics, 41 (8), 981-997 - doi: 10.1007/s40273-023-01277-4 - [link]
Brenda Leeneman, Hedwig M. Blommestein, Annemieke van Dongen-Leunis, Mattia Algeri, Willem E. Fibbe, Liesbeth Oosten, Carin A. Uyl-de Groot & Frederick W. Thielen (2023) - Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease - European Journal of Haematology, 111 (2), 240-246 - doi: 10.1111/ejh.13987 - [link]
Christine Bennink, Hans Westgeest, Daan Schoonen, Femke Boersen, Pieter Sonneveld, Jan Hazelzet, Hedwig Blommestein & Marjolein Van Der Klift (2023) - High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study - HemaSphere, 7 (6) - doi: 10.1097/HS9.0000000000000913 - [link]
Marianne Luyendijk, Otto Visser, Hedwig M. Blommestein, Ignace H.J.T. de Hingh, Frank J.P. Hoebers, Agnes Jager, Gabe S. Sonke, Elisabeth G.E. de Vries, Carin A. Uyl-de Groot & Sabine Siesling (2023) - Changes in survival in de novo metastatic cancer in an era of new medicines - Journal of the National Cancer Institute, 115 (6), 628-635 - doi: 10.1093/jnci/djad020 - [link]
Lj Bakker, Fw Thielen, Wk Redekop, CA Uyl de Groot & Hm Blommestein (2023) - Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma - BMC Medical Research Methodology, 23 (1) - doi: 10.1186/s12874-023-01952-2 - [link]
Marianne Luyendijk, Hedwig Blommestein, Carin Uyl-de Groot, Sabine Siesling & Agnes Jager (2023) - Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands - JAMA network open, 6 (2) - doi: 10.1001/jamanetworkopen.2022.56170 - [link]
Elisabeth M. Jongbloed, Hedwig M. Blommestein, Hannah M. van Schoubroeck, John W.M. Martens, Saskia M. Wilting, Carin Uyl-de Groot & Agnes Jager (2023) - Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs? - Breast Cancer: Targets and Therapy, 15, 147-161 - doi: 10.2147/BCTT.S387375 - [link]